Clinical Trial of DA-5212 in Patients with Functional Dyspepsia

NCT05842408 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 384

Last updated 2024-12-13

No results posted yet for this study

Summary

This study is to evaluate efficacy and safety of DA-5212 in patients with functional dyspepsia

Conditions

  • Functional Dyspepsia

Interventions

DRUG

DA-5212

Test drug: DA-5212

DRUG

DA-5212-R

Control drug: DA-5212-R

Sponsors & Collaborators

  • Dong-A ST Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-06
Primary Completion
2024-09-04
Completion
2024-09-04

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05842408 on ClinicalTrials.gov